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Philpott, Dougherty, Reed et al highlight the important issue of adrenal suppression (AS) as a 
complication of corticosteroid therapy in their systematic review of AS in eosinophilic oesophagitis.  
They conclude that a “non-trivial minority” of patients had abnormal cortisol values (crude rate of 
15.8%) but correctly point out that the preference for random serum cortisol measurements rather 
than dynamic ACTH stimulation testing risks underestimating the true incidence of this well-
recognised, potentially serious, complication of corticosteroid therapy.
1
 
We carried out a Europe-wide survey of practice to assess current practice regarding screening of 
adrenal suppression in inflammatory bowel disease (IBD) in children. A comprehensive systematic 
review of adrenal suppression in paediatric IBD is currently lacking, but individual studies have 
reported rates between 20% and 89%.
2,3
 
In the paediatric population, a 10 week course of systemic glucocorticoids is frequently prescribed to 
induce remission
4
, the cumulative dose of which has long been recognised to have the potential to 
suppress the hypothalamic-pituitary-adrenal axis for up to a year post-treatment
5
.  Symptoms of AS 
can range from life-threatening adrenal crisis to more subtle chronic symptoms including fatigue, 
abdominal pain and diarrhoea.  The latter clearly have the potential to mimic IBD symptoms and 
lead to inappropriate escalation of immunosuppressive treatment.  
Our electronic survey was sent to clinicians at 113 tertiary centres for paediatric IBD via mailing lists 
to members of the British Society of Paediatric Gastroenterology, Hepatology and Nutrition 
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(BSPGHAN), and the IBD working group of the European Society of Gastroenterology, Hepatology 
and Nutrition (ESPGHAN), which includes the expert Paediatric IBD Porto group; forty nine responses 
were returned (43% return rate).  Although all clinicians were aware of AS as a potential side effect 
of glucocorticoid treatment, only 74% had ever tested a patient for AS, with investigation(s) 
performed most commonly after prolonged courses of steroids (i.e. beyond the standard 10-week 
course) and/or in the presence of AS symptoms. Clinicians from the UK were not statistically more 
likely to do any testing compared to international clinicians (91% [20/22] vs 72% [13/18] (p = 0.26). 
(Fig 1) 
Of those that did any testing for adrenal suppression, 17/33 (52%) used a standard or low dose ACTH 
stimulation test and 15/33 (45%) used early morning cortisol levels.  Timing of investigation(s) varied 
considerably, from during the final phase of treatment (e.g. 1-5mg prednisolone per day) to months 
after the course had finished.  
These results highlight the high degree of variability in practice across Europe when screening for 
adrenal suppression in children with IBD.  This is in stark contrast to other specialties who have 
adopted a more consistent approach, notably screening of children receiving high dose inhaled 
corticosteroids for asthma, following high profile fatalities and a recognition of the morbidity of 
chronic adrenal insufficiency symptoms
6
.  Following on from Philpott and Dougherty’s work in 
eosinophilic oesophagitis, a comprehensive review of literature reporting rates of adrenal 
suppression in inflammatory bowel disease is also needed, as well as prospective studies (ideally 
using ACTH stimulation testing) in both these populations, to better inform what is currently a highly 
variable practice. 
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Figure 1 legend Figure 1. Responses to question: “Do you routinely test for adrenal suppression in 
your IBD patients completing a course of glucorticoid (steroid) therapy?)” (more than one response 
allowed) 
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Figure 1. Responses to question: “Do you routinely test for adrenal suppression in your IBD patients 
completing a course of glucorticoid (steroid) therapy?)” (more than one response allowed) 
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